Abstract:Hepatocellular carcinoma (HCC) is the third leading cause of liver-related death. Lipophilic statins have been associated with a decrease in HCC incidence, raising the possibility of their use as chemoprevention agents. The Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) have emerged as an important pro-oncogenic mechanism in HCC. Statins modulate YAP/TAZ in other solid tumors, but few studies have assessed their mechanisms in HCC. We aimed to delineate how lipophilic statins regulate YAP protein localization by interrogating the mevalonate pathway in a stepwise manner using pharmacological and genetical approaches in HCC cells. Huh7 and Hep3B HCC cells were treated with the lipophilic statins cerivastatin and atorvastatin. YAP protein localization was determined using quantitative immunofluorescence (IF) imaging. The gene expression of CTGF and CYR61, known YAP/TEA-domain DNA-binding factor (TEAD)-regulated genes, was measured using quantitative real-time PCR. Rescue experiments were conducted using metabolites of the mevalonate pathway including mevalonic acid and geranylgeranyl pyrophosphate (GG-PP). The cellular cytoskeleton was assessed using F-actin IF staining. YAP protein was extruded from the nucleus to the cytoplasm with statin treatment. Consistently, CTGF and CYR61 mRNA expression significantly decreased with statins. Cytoskeletal structure was also compromised with statins. Gene expression, YAP protein localization, and cytoskeletal structure were all restored to baseline with exogenous GG-PP but not with other metabolites of the mevalonate pathway. Direct Rho GTPase inhibitor treatment mirrored the statin effects on YAP. YAP protein localization is regulated by lipophilic statins via Rho GTPases, causing cytoskeletal structural changes and is independent of cholesterol metabolites.NEW & NOTEWORTHY Statins are widely used for the treatment of cardiovascular diseases. Recently, their use has been associated with a decrease in the incidence of hepatocellular carcinoma (HCC); however, their mechanism(s) has remained elusive. In this study, we delineate the mechanism by which statins affect the Yes-associated protein (YAP), which has emerged as a key oncogenic pathway in HCC. We investigate each step of the mevalonate pathway and demonstrate that statins regulate YAP via Rho GTPases.

Ott_a_237693 2057..2066

Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and β-Catenin Signaling.

Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis Via AKT/mTOR, ERK and JAK2/STAT3 Pathway

Key roles of Rho GTPases, YAP, and Mutant P53 in anti-neoplastic effects of statins

Effects of HMG-CoA Reductase Inhibitors on Proliferation and Growth of Gastric Cancer Cells in Vitro

Activation of AMPK by Simvastatin Inhibited Breast Tumor Angiogenesis Via Impeding HIF-1-induced Pro-Angiogenic Factor

Stigmasterol Simultaneously Induces Apoptosis and Protective Autophagy by Inhibiting Akt/mTOR Pathway in Gastric Cancer Cells

Simvastatin Inhibits Proliferation and Promotes Apoptosis of Oral Squamous Cell Carcinoma Through KLF2 Signal.

Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice

Simvastatin suppresses cell migration and invasion , induces G 0 / G 1 cell cycle arrest and apoptosis in osteosarcoma cells

Proteome and phosphoproteome reveal mechanisms of action of atorvastatin against esophageal squamous cell carcinoma

Simvastatin induces ferroptosis and activates anti-tumor immunity to sensitize anti-PD-1 immunotherapy in microsatellite stable gastric cancer

Simvastatin Inhibits Proliferation and Induces Apoptosis in Human Lung Cancer Cells.

The mechanism of lovastatin in suppressing the proliferation of esophageal squamous cell carcinoma based on proteomics

Targeting Cholesterol Biosynthesis Promotes Anti-Tumor Immunity by Inhibiting Long Noncoding RNA SNHG29-mediated YAP Activation.

Stigmasterol Exhibits Potent Antitumor Effects in Human Gastric Cancer Cells Mediated Via Inhibition of Cell Migration, Cell Cycle Arrest, Mitochondrial Mediated Apoptosis and Inhibition of JAK/STAT Signalling Pathway.

Involvement of Chk1–Cdc25A-cyclin A/CDk2 Pathway in Simvastatin Induced S-phase Cell Cycle Arrest and Apoptosis in Multiple Myeloma Cells

Simvastatin induces pyroptosis via ROS/caspase-1/GSDMD pathway in colon cancer

Lipophilic statins inhibit YAP coactivator transcriptional activity in HCC cells through Rho-mediated modulation of actin cytoskeleton

Effect of Simvastatin on apoptosis and expressions of Bax and Bcl-2 gene in human gastric cancer cell line SGC7901

Simvastatin Preferentially Targets FLT3 /ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways